India Bans Over-the-Counter Sale of Cough Syrups - Prescription Now Mandatory Nationwide

The Union Ministry of Health and Family Welfare has ended over-the-counter sales of all syrup-based medicines, including cough syrups, across India. Effective June 9, 2026, consumers must present a valid prescription from a registered medical practitioner to purchase these medicines from any licensed pharmacy. The move follows years of regulatory action triggered by child deaths linked to contaminated cough syrups in India and abroad.

Quick Facts

  • Issuing Authority: Union Ministry of Health and Family Welfare, Government of India
  • Effective Date: June 9, 2026 (gazette notification date)
  • Legal Instrument: Drugs (Fifth Amendment) Rules, 2026 - amending the Drugs Rules, 1945
  • Key Change: The word "Syrups" removed from item number (7) under serial number 13 of Schedule K of the Drugs Rules, 1945
  • Consultation Body: Drugs Technical Advisory Board
  • Draft Notification Released: December 30, 2025
  • Additional Restriction: Sale of cough syrups in villages with populations below 1,000 has been disallowed
  • Dispensing Requirement: Only through duly licensed pharmacies under the Drugs and Cosmetics Act, 1940

What Happened?

The Union Ministry of Health and Family Welfare issued a gazette notification on June 9, 2026, formally enacting the Drugs (Fifth Amendment) Rules, 2026. The amendment removes the word "Syrups" from Schedule K of the Drugs Rules, 1945 - a list that had previously exempted certain medicines, including syrups, from standard sale-licensing requirements. By removing syrups from Schedule K, the government has brought all syrup-based medicines, including commonly used cough syrups, under the full regulatory framework of the Drugs and Cosmetics Act, 1940. Consumers across India must now produce a valid prescription from a registered doctor to purchase any syrup-based medicine from a licensed pharmacy. The rule also bars the sale of such medicines in villages with populations under 1,000 people, further tightening access to these products.

The amendment followed a draft notification published on December 30, 2025, which invited public objections and suggestions for a 30-day period. The government reviewed all comments received before finalising the rule, in exercise of powers granted under Sections 12 and 33 of the Drugs and Cosmetics Act, 1940, and after consultation with the Drugs Technical Advisory Board.

Key Facts

  • All syrup-based medicines, including cough syrups, are now prescription-only medicines (Schedule H category requirements apply).
  • The legal basis for the change is the removal of "Syrups" from Schedule K of the Drugs Rules, 1945, which had exempted them from prescription requirements.
  • The Drugs (Fifth Amendment) Rules, 2026 were notified in the Official Gazette on June 9, 2026.
  • A draft proposal for the change was first released on December 30, 2025, and public comments were examined before finalisation.
  • The amendment was made after consultation with the Drugs Technical Advisory Board, as required under the Drugs and Cosmetics Act, 1940.
  • Sale in villages with a population below 1,000 is now prohibited.
  • In 2023, the government had introduced mandatory testing of cough syrups before export.
  • In October 2025, the government called for online tracking of high-risk solvents used in syrup products.
  • Prior incidents include child deaths in Madhya Pradesh and Rajasthan linked to contaminated cough syrups, as well as international child deaths linked to India-manufactured syrups flagged by the World Health Organisation in 2023.

Why It Matters

Cough syrups and other liquid medicines have historically been among the most accessible over-the-counter products available in Indian pharmacies and even general stores. The Schedule K exemption allowed these medicines to be sold without a prescription under certain conditions - a system that critics argued facilitated widespread misuse and limited accountability in the supply chain. The new rule marks one of the most significant shifts in Indian drug retail policy in decades, bringing syrup-based medicines under the same regulatory oversight as other prescription drugs.

The move is directly connected to a series of contamination tragedies. Children in Madhya Pradesh and Rajasthan reportedly died after consuming adulterated or substandard cough syrups. On the international front, the WHO issued a global alert in 2023 after adulterated cough syrups manufactured in India were linked to child deaths in other countries, damaging India's pharmaceutical export reputation. The prescription requirement is intended to create an additional layer of accountability - ensuring that medical oversight accompanies the dispensing of these medicines.

What It Means for India

For millions of Indian consumers, this regulatory change alters a deeply ingrained habit. Cough syrups have long been among the first medicines purchased without a doctor's visit - available at neighbourhood pharmacies and, under Schedule K provisions, even at general stores. The new rule means that any consumer seeking a cough syrup must now first visit a registered doctor, obtain a written prescription, and then present it at a licensed pharmacy.

The rule also has significant implications for rural India. The explicit bar on sales in villages with populations below 1,000 reflects a recognition that unlicensed or informal distribution channels are more prevalent in smaller communities. While the intent is to improve safety, access to licensed pharmacies in remote and rural areas remains uneven, which could create challenges for patients who genuinely need these medicines.

For India's pharmaceutical industry, the change tightens oversight across the supply chain - from manufacture through distribution to retail - and aligns domestic standards more closely with international regulatory expectations, which is particularly relevant given India's status as one of the world's largest manufacturers and exporters of generic medicines.

Industry Impact

India's pharmaceutical sector, particularly companies that manufacture and market cough syrups and other liquid medicines as over-the-counter products, will face direct impact. The removal of cough syrups from Schedule K exemptions means that distribution networks previously relying on general trade channels - including non-licensed retail outlets - must now be restructured to comply with prescription-only requirements. Pharmaceutical companies will need to review their marketing, labelling, packaging, and distribution frameworks.

The broader Indian pharmaceutical industry had already been under heightened scrutiny following international incidents. The WHO alert in 2023 and subsequent enforcement actions had already prompted manufacturers to improve quality controls on export-bound products. The domestic prescription mandate extends similar accountability to products sold within India, which could require additional investment in quality assurance and regulatory compliance infrastructure across the industry.

Latest Developments

The gazette notification was issued on June 9, 2026, putting the Drugs (Fifth Amendment) Rules, 2026 into immediate effect. The regulation was reported widely in Indian media on June 16, 2026. Prior to this notification, the government had already introduced mandatory pre-export testing of cough syrups in 2023 and called for online tracking of high-risk solvents used in pharmaceutical products in October 2025. The December 2025 draft notification was the direct precursor to the final amendment.

State-level actions had also preceded the national rule. In October 2025, the Uttar Pradesh government banned the Coldrif brand of cough syrup manufactured by Shreesan Pharmaceutical following reports of severe adverse effects and child deaths across states. In January 2026, the Puducherry government banned the sale of three cough syrups after quality failures. These state-level moves reflected mounting pressure on the central government to act on syrup safety at a national level.

Top India News Analysis

The Drugs (Fifth Amendment) Rules, 2026 represent the culmination of a regulatory response that has been building for several years. The trajectory - from WHO alerts in 2023, to export testing mandates, to solvent tracking requirements, to state-level bans, and now to a national prescription mandate - reflects a pattern of escalating regulatory action in response to documented public health failures.

The central challenge now moves from legislation to implementation. India's pharmacy infrastructure, particularly in semi-urban and rural areas, has historically operated with varying degrees of compliance. Enforcing prescription requirements for products that were previously sold freely will require sustained monitoring by state drug control authorities. The ban on sales in villages with populations under 1,000 further signals that the government is aware of informal distribution patterns, though the practical mechanisms for enforcement in remote areas remain to be tested.

Key Takeaways

  • The Union Ministry of Health and Family Welfare has banned over-the-counter sales of cough syrups and all syrup-based medicines nationwide, effective June 9, 2026.
  • A valid prescription from a registered medical practitioner is now mandatory for the purchase of any syrup-based medicine from a licensed pharmacy.
  • The change was made through the Drugs (Fifth Amendment) Rules, 2026, by removing "Syrups" from Schedule K of the Drugs Rules, 1945.
  • Sale of cough syrups in villages with populations below 1,000 has also been explicitly prohibited.
  • The regulation follows child deaths linked to contaminated cough syrups in India and a WHO global alert in 2023 over India-manufactured syrups linked to international child deaths.
  • The amendment was finalised after a public consultation process initiated by a draft notification released on December 30, 2025.
  • India had previously introduced mandatory export testing of cough syrups in 2023 and online tracking of high-risk solvents in October 2025.
  • The rule has significant implications for both consumers and the pharmaceutical industry, requiring restructuring of distribution and retail practices.

Sources Consulted

  • ANI (Asian News International) - Centre mandates prescription for syrup medicines, including cough syrups, bars over-the-counter sale, June 16, 2026
  • India TV News - Cough syrup purchase only with prescription from now on as Centre bans over-the-counter sales, June 16, 2026
  • Oneindia News - No More Over-the-Counter Cough Syrups: Centre Makes Prescription Compulsory Under New Drug Rules, June 16, 2026
  • Northeast News - Centre bans over-the-counter sale of cough syrups, mandates doctor's prescription, June 16, 2026
  • New Kerala - Prescription Now Mandatory for Syrup Medicines in India, June 16, 2026
  • Deccan Herald - Health Ministry moves to remove syrups as OTC medicine, ban Nimesulide (background, December 2025 draft notification)
  • Newsonair (All India Radio) - UP Government Bans Coldrif Cough Syrup After Child Deaths, Launches Probe, October 6, 2025
  • Newsonair (All India Radio) - Puducherry bans sale of three cough syrups over quality concerns, January 23, 2026
  • WION News - India: Health Ministry Bans Over The Country Sale of Syrup (source image provided)

Author: Manjula Devi R

Publisher: Top India News